The goal of this clinical trial is to test if the drug SKY-0515, an oral medication, can lower harmful proteins linked to Huntington's Disease (HD) and improve the symptoms of participants with HD. This study includes men and women aged 25 and older who have HD confirmed by genetic testing and meet certain requirements for physical ability and independence.
25 years or older.
Huntington's Disease confirmed through genetic testing, with a specific change in exon 1 of the HTT gene (CAG repeat of 40 or more).
Total Functional Capacity (TFC) score of 10 or more).
Total Motor Score (TMS) of 6 or more).
Other Serious health problems or brain/spinal issues that could interfere with the study or make procedures unsafe.
Conditions that interfere with protocol-specified assessments, like an implanted medical device or difficulty getting an MRI.
Cancer, except for some types of skin cancer, or a history of cancer in the last five years.
Severe allergies or have reacted badly to similar drugs in the past.